PulseSight to highlight new data on the role of iron and transferrin in AMD at EURETINA 2025

(Image credit: ©BillionPhotos.com/AdobeStock)

PulseSight Therapeutics announced the presentation of new data on iron dysregulation and the role of ferroptosis in age-related macular degeneration (AMD). This presentation will be given by Thierry Bordet, PhD, chief scientific officer of PulseSight, during the 2025 European Society of Retina Specialists Annual Congress held September 4-7 in Paris.

In collaboration with Inserm and Cochin Hospital (Paris) and using one of the largest aqueous humor datasets to date, PulseSight explored iron-transferrin imbalance in dry AMD and geographic atrophy (GA) patients compared to age-matched controlled patients.¹

The collaborative study found and confirmed elevated iron and increased transferrin saturation in aqueous humors of AMD patients.

“Ferroptosis is now a well-recognized target in AMD pathology,” Bordet said in a press release. “At PulseSight, we’ve designed a translational strategy to restore iron homeostasis and prevent ferroptosis.”

PulseSight’s lead therapy, PST-611, is a first-in-class non-viral vectorized therapy encoding transferrin to restore iron balance and preserve retinal structure and function in dry AMD and GA.¹ PST-611 encodes the human transferrin protein, which is a crucial regulator of iron homeostasis, and only requires re-treatment every four to six months.

The recent findings further support the development of PST-611, which entered a phase 1 clinical trial (PST-611-CT1) in January 2025.² The company announced the successful dosing of the first patient in the phase 1 clinical trial PST-611-CT1 in July 2025.³

PST-611-CT1 is a single ascending dose study aimed at establishing the safety profile of PST-611 and validating the maximal tolerated dose in 6-12 patients enrolled with dry AMD and GA.³

“With PST-611, we combine mechanistic relevance, long-lasting efficacy, and a de-risked delivery platform,” Bordet said.

Additionally, Bordet will present topline data from a specific study conducted to provide mechanistic insights into the role of transferrin in preventing ferroptosis. The study’s full results have been submitted for peer-reviewed publication.¹

Reference:

1. Morningstar I. PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025. Morningstar, Inc. Published September 4, 2025. Accessed September 4, 2025. https://www.morningstar.com/news/globe-newswire/1001126185/pulsesight-therapeutics-provides-new-insights-into-the-role-of-iron-and-transferrin-in-amd-supporting-its-pst-611-vectorized-therapy-for-dry-amdgeographic-atrophy-at-euretina-2025

2. PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy – Pulsesight. Pulsesight.com. Published 2025. Accessed September 4, 2025. https://pulsesight.com/2025/01/14/pulsesight-therapeutics-announces-the-initiation-of-the-clinical-plan-of-pst-611-transferrin-vectorized-therapy-for-dry-amd-geographic-atrophy/

3. Filkins K. PulseSight doses first patient in PST-611-CT1. Ophthalmology Times. Published July 9, 2025. Accessed September 4, 2025. https://www.ophthalmologytimes.com/view/pulsesight-doses-first-patient-in-pst-611-ct1